Hepatitis C (HCV) - Pipeline Assessment And Market Forecasts To 2016 - New Market Report Published

Published on July 05, 2010

by Press Office
(Companiesandmarkets.com and OfficialWire)
LONDON, ENGLAND

Hepatitis C (HCV) - Pipeline Assessment and Market Forecasts to 2016 ; The report is an essential source of information and analysis on the global HCV market. The report identifies the key trends shaping and driving the global HCV market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to cause significant shifts in the positioning of the existing market leaders.

Most importantly, the report provides valuable insight into the pipeline products within the global hepatitis C sector. The analysis suggests that the global HCV market was worth $4.4 billion in 2009. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.8% for the next seven years to reach $8.5 billion by 2016. The high projected growth rate is primarily attributable to a strong pipeline.

The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. We found that the global HCV market is becoming more competitive. When seen alongside the currently marketed products and the expectations of patients and physicians, the pipeline is considered to be strong. The unmet need in the HCV is high and if a company wants to capture this unmet need, it will need to overcome the prevailing product weaknesses and adverse effects.

Scope

The scope of the report includes:

- Annualized global hepatitis C market revenues data from 2000 to 2009, forecast for seven years to 2016.

- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include protease inhibitors, polymerase inhibitors, toll receptor agonists, drugs with interferon-like actions, HCV inhibitors and immunomodulators.

- Analysis of the current and future market competition in the global hepatitis C market. The key market players covered are Merck, Human Genome Sciences, Novartis, Vertex, Janssen, Mitsubishi, Tibotec and Roche.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future hepatitis C market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global hepatitis C market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global hepatitis C market landscape? - Identify, understand and capitalize.

Hepatitis C (HCV) - Pipeline Assessment and Market Forecasts to 2016: http://www.companiesandmarkets.com/r.ashx?id=28R2681T1317468&prk=1f4af2510d0eeb545303566fd466b33e

Source